Could GLP-1 receptor agonists be used to treat binge eating disorder? Binge eating disorder is one of the most common eating disorders, yet treatment options remain limited. Now widely used for type 2 diabetes and weight management, Glucagon-like peptide (GLP)-1 receptor agonists act on pathways involved in appetite and food intake, but little is known about how these medications affect disordered eating behaviours, including binge eating, emotional eating, loss of control eating, and dietary restraint.
In this episode, Dr Ilaria Costantini joins eClinicalMedicine Senior Editor Victoria Higgs to discuss her new systematic review and meta-analysis, which draws on data from 25 clinical trials and more than 8000 participants, alongside valuable personal insights from people with lived experience. They explore evidence that GLP-1 receptor agonists may reduce binge eating-related behaviours, while also considering concerns that these medications could affect eating restraint or body image in a harmful way and why psychological support might be key for their use. This conversation examines the limitations of current evidence and next steps for research at the intersection of metabolic medicines and eating disorders.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av,
eller tillsammans med, Poddtoppen.
